CIPLA(Cipla Limited)
25.11.2022 - HSBC on Cipla Maintain Buy CMP 1097.1 Target 1340
19.09.2022 - Nomura on Cipla Maintain Buy CMP 1027.45 Target 1195
16.09.2022 - Jefferies on Cipla Maintain Buy CMP 1043.9 Target 1223
01.08.2022 - CS on Cipla Maintain Outperform CMP 1005 Target 1100
01.08.2022 - GS on Cipla Maintain Sell CMP 1005 Target 850
01.08.2022 - HSBC on Cipla Maintain Outperform CMP 1005 Target 1180
01.08.2022 - Nomura on Cipla Maintain Buy CMP 1005 Target 1195
01.08.2022 - MS on Cipla Maintain Overweight CMP 1005 Target 1122
06.06.2022 - CITI on Cipla Maintain Buy CMP 963.7 Target 1170
11.05.2022 - CS on Cipla Maintain Outperform CMP 926 1100
11.05.2022 - MS on Cipla Maintain Overweight CMP 926 1122
11.05.2022 - Jefferies on Cipla Maintain Buy CMP 926 Target 1165
11.05.2022 - GS on Cipla Maintain SELL CMP 926 Target 850
22.03.2022 - BOFA on Cipla Maintain Underperform CMP 1050 Target 860
27.01.2022 - Jefferies on CIPLA Maintain Buy CMP 906 Target 1093
27.01.2022 - CITI on CIPLA Maintain Buy CMP 906 Target 1120
27.01.2022 - CLSA on CIPLA Maintain Buy CMP 906 Target 1150
24.01.2022 - CS on CIPLA Maintain Outperform CMP 892 Target 1150
20.12.2021 - Nomura On Cipla - Maintain Buy - CMP 856 - Target 1051
GOLDMAN SACHS ON CIPLA Maintain Neutral TGT 890 : 17.05.2021
* Goldman Sachs maintains Neutral call on Cipla after co misses its estimates in Q4
* MAINTAIN NEUTRAL TARGET: 890
* Reported Q4 Miss, Led By A 200 bps Gross Margin Impact
* Gross Margin Impacted From Shelf Stock Adjustments In US & Inventory Write-offs
* Seasonal Weakness Pronounced On Absence Of Flu Season In Both India & Key Mkts
MORGAN STANLEY ON CIPLA Maintain Overweight TGT 949 : 17.05.2021
* Morgan Stanley has an Overweight call on Cipla with a target of Rs 949/sh
* MAINTAIN OVERWEIGHT TARGET: 949
* Co Continues To Strengthen Its Base Biz In India, US & South Africa
* US Inhaler Pipeline Is Looking Deep With Several Late-stage Pdts
GOLDMAN SACHS ON CIPLA Maintain Neutral TGT 890 : 17.05.2021
* Maintain Neutral, Target at Rs 890/share
* Gross margin impact from shelf stock adjustments on gProventil in the US
* Cipla indicated that it is supplying 5x more Remdesivir units
* Cipla also sees room to improve on the current ~22.5% EBITDA margin
JPMORGAN ON CIPLA : 17.05.2021
* JPMorgan has a Neutral call on Cipla as US biz & margin disappoint
* MAINTAIN NEUTRAL TARGET: 785
* Weak Earnings As US & Margin Disappoint
* Disappointed By US Sales Despite Albuterol Ramp-up & Muted Gross Margin
* Management Guided To Maintaining Or Improving Upon The FY21 Margin Of 22%